Published in J Am Coll Cardiol on March 07, 2006
Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol (2011) 1.55
Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson (2012) 1.51
Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations. J Am Coll Cardiol (2014) 1.47
Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. J Am Coll Cardiol (2007) 1.29
Coronary microvascular dysfunction in the clinical setting: from mystery to reality. Eur Heart J (2012) 1.07
Hypertrophic cardiomyopathy in 2012. Circulation (2012) 0.98
Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc Res (2015) 0.96
Coronary flow reserve in hypertrophic cardiomyopathy: relation with microvascular dysfunction and pathophysiological characteristics. Neth Heart J (2007) 0.93
Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging (2013) 0.86
Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy: Insights From Wave Intensity Analysis and Magnetic Resonance. J Am Coll Cardiol (2016) 0.84
Quantitative cardiac positron emission tomography: the time is coming! Scientifica (Cairo) (2012) 0.82
Peripheral vascular endothelial function in patients with hypertrophic cardiomyopathy. Am J Cardiol (2010) 0.82
Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal. Eur J Nucl Med Mol Imaging (2016) 0.80
Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM). Eur J Nucl Med Mol Imaging (2016) 0.78
Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a (13)NH3 gated PET study. Eur J Nucl Med Mol Imaging (2017) 0.78
Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies. Heart Fail Rev (2017) 0.77
Long-term prognostic value of coronary flow velocity reserve in patients with hypertrophic cardiomyopathy: 9-year follow-up results from SZEGED study. Heart Vessels (2009) 0.76
Clinical Characteristics and Prognosis of End-stage Hypertrophic Cardiomyopathy. Chin Med J (Engl) (2015) 0.76
Slow Coronary Flow is Related to Increased Carotid Intima-Media Thickness but Not Pulse Wave Velocity. Korean Circ J (2011) 0.75
Extent of late gadolinium enhancement at right ventricular insertion points in patients with hypertrophic cardiomyopathy: relation with diastolic dysfunction. Eur Radiol (2015) 0.75
A One Health Approach to Hypertrophic Cardiomyopathy. Yale J Biol Med (2017) 0.75
3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging (2017) 0.75
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2007) 6.34
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med (2003) 5.17
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation (2006) 3.82
Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med (2003) 2.92
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol (2008) 2.82
Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc (2008) 2.80
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol (2005) 2.43
Myocardial oxygenation in coronary artery disease: insights from blood oxygen level-dependent magnetic resonance imaging at 3 tesla. J Am Coll Cardiol (2012) 2.38
Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol (2007) 2.22
Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes. Catheter Cardiovasc Interv (2009) 2.07
Functional changes in coronary microcirculation after valve replacement in patients with aortic stenosis. Circulation (2003) 1.91
Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J (2011) 1.82
Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol (2010) 1.80
Myocardial blood flow measurement by PET: technical aspects and clinical applications. J Nucl Med (2005) 1.74
Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol (2006) 1.66
The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol (2009) 1.66
Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol (2006) 1.65
Relationship between regional myocardial oxygenation and perfusion in patients with coronary artery disease: insights from cardiovascular magnetic resonance and positron emission tomography. Circ Cardiovasc Imaging (2009) 1.61
Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol (2013) 1.60
Systemic inhibition of nitric oxide synthase unmasks neural constraint of maximal myocardial blood flow in humans. Circulation (2004) 1.59
Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol (2007) 1.58
Absolute quantification of myocardial blood flow with H(2)(15)O and 3-dimensional PET: an experimental validation. J Nucl Med (2002) 1.57
Cytogenetic and molecular evaluation of 241 small supernumerary marker chromosomes: cooperative study of 19 Italian laboratories. Genet Med (2005) 1.53
Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis. Am J Kidney Dis (2006) 1.49
Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol (2007) 1.47
Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. Am J Cardiol (2010) 1.46
Anatomic versus physiologic assessment of coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. J Am Coll Cardiol (2013) 1.44
Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy. Eur J Nucl Med Mol Imaging (2015) 1.41
Detecting common copy number variants in high-throughput sequencing data by using JointSLM algorithm. Nucleic Acids Res (2011) 1.40
Comparison of myocardial blood flow and coronary flow reserve during dobutamine and adenosine stress: Implications for pharmacologic stress testing in coronary artery disease. J Nucl Cardiol (2006) 1.39
Patent foramen ovale closure and brain ischaemic lesions. Heart (2013) 1.39
[Management of refractory symptoms in hypertrophic cardiomyopathy with restrictive pathophysiology: novel perspectives for ranolazine]. G Ital Cardiol (Rome) (2012) 1.38
Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries. Circulation (2002) 1.36
Gross genomic rearrangements involving deletions in the CFTR gene: characterization of six new events from a large cohort of hitherto unidentified cystic fibrosis chromosomes and meta-analysis of the underlying mechanisms. Eur J Hum Genet (2006) 1.33
De novo balanced chromosome rearrangements in prenatal diagnosis. Prenat Diagn (2009) 1.29
Coronary microvascular dysfunction: an update. Eur Heart J (2013) 1.28
Program of cell survival underlying human and experimental hibernating myocardium. Circ Res (2004) 1.27
Coronary microvascular resistance: methods for its quantification in humans. Basic Res Cardiol (2009) 1.26
Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J (2009) 1.26
Read count approach for DNA copy number variants detection. Bioinformatics (2011) 1.23
Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging (2010) 1.19
Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol (2005) 1.18
Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2002) 1.18
The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. J Physiol (2008) 1.14
Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res (2008) 1.14
Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2003) 1.13
Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J (2009) 1.12
Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. Eur Heart J (2011) 1.11
Respiratory gating of cardiac PET data in list-mode acquisition. Eur J Nucl Med Mol Imaging (2006) 1.10
Th2-oriented profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. Arthritis Rheum (2002) 1.09
Evaluation of the microcirculation in hypertension and cardiovascular disease. Eur Heart J (2007) 1.09
Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J (2012) 1.08
Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol (2007) 1.07
Can silent brain lesions be a target to guide anticoagulation treatment in patients with low-risk atrial fibrillation to reduce cognitive impairment? J Am Coll Cardiol (2014) 1.06
EX-HOM (EXome HOMozygosity): a proof of principle. Hum Hered (2011) 1.06
Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography. J Am Coll Cardiol (2010) 1.05
Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol (2011) 1.03
Cardiovascular events in patients with fabry disease natural history data from the fabry registry. J Am Coll Cardiol (2011) 1.03
Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail (2012) 1.01
Discovering chimeric transcripts in paired-end RNA-seq data by using EricScript. Bioinformatics (2012) 1.01
Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. Nat Rev Cardiol (2009) 1.01
A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown) (2006) 1.01
Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes (2002) 1.00
Expression and function of gonadotropin-releasing hormone (GnRH) receptor in human olfactory GnRH-secreting neurons: an autocrine GnRH loop underlies neuronal migration. J Biol Chem (2003) 0.99
Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J (2012) 0.98
Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging (2013) 0.97
Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. Lung Cancer (2013) 0.96
A shifting level model algorithm that identifies aberrations in array-CGH data. Biostatistics (2009) 0.96
Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound (2010) 0.96
Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in tuscany. Am J Cardiol (2003) 0.95
Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy. J Cardiovasc Transl Res (2009) 0.95
Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace (2010) 0.94
Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome. Circulation (2004) 0.93
[Percutaneous coronary interventions. Guidelines of the European Society of Cardiology-ESC]. Kardiol Pol (2005) 0.93
Determinants of echocardiographic left atrial volume: implications for normalcy. Eur J Echocardiogr (2011) 0.93
The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice. J Cardiovasc Transl Res (2009) 0.92
Absolute blood flow and oxygen consumption in stunned myocardium in patients with coronary artery disease. J Am Coll Cardiol (2002) 0.91
Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J (2010) 0.91
Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. J Nucl Med (2008) 0.91
The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica (2008) 0.91